» Articles » PMID: 24133413

Neuronal Dark Matter: the Emerging Role of MicroRNAs in Neurodegeneration

Overview
Specialty Cell Biology
Date 2013 Oct 18
PMID 24133413
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) are small, abundant RNA molecules that constitute part of the cell's non-coding RNA "dark matter." In recent years, the discovery of miRNAs has revolutionised the traditional view of gene expression and our understanding of miRNA biogenesis and function has expanded. Altered expression of miRNAs is increasingly recognized as a feature of many disease states, including neurodegeneration. Here, we review the emerging role for miRNA dysfunction in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Huntington's disease pathogenesis. We emphasize the complex nature of gene regulatory networks and the need for systematic studies, with larger sample cohorts than have so far been reported, to reveal the most important miRNA regulators in disease. Finally, miRNA diversity and their potential to target multiple pathways, offers novel clinical applications for miRNAs as biomarkers and therapeutic agents in neurodegenerative diseases.

Citing Articles

An Update on Neuroaging on Earth and in Spaceflight.

Kuznetsov N, Statsenko Y, Ljubisavljevic M Int J Mol Sci. 2025; 26(4).

PMID: 40004201 PMC: 11855577. DOI: 10.3390/ijms26041738.


Blood-based microRNAs as the potential biomarkers for Alzheimer's disease: evidence from a systematic review.

Fattahi F, Asadi M, Abed S, Kouchakali G, Kazemi M, Mansoori Derakhshan S Metab Brain Dis. 2024; 40(1):44.

PMID: 39607566 DOI: 10.1007/s11011-024-01431-7.


Therapeutic Strategies in Advanced Cervical Cancer Detection, Prevention and Treatment.

Sebutsoe X, Tsotetsi N, Jantjies Z, Raphela-Choma P, Choene M, Motadi L Onco Targets Ther. 2024; 17:785-801.

PMID: 39345275 PMC: 11439348. DOI: 10.2147/OTT.S475132.


MicroRNA-455-3P as a peripheral biomarker and therapeutic target for mild cognitive impairment and Alzheimer's disease.

Islam M, Sultana O, Bandari M, Kshirsagar S, Manna P, Reddy P Ageing Res Rev. 2024; 100:102459.

PMID: 39153602 PMC: 11383742. DOI: 10.1016/j.arr.2024.102459.


MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review.

Azam H, Rossling R, Geithe C, Khan M, Dinter F, Hanack K Front Mol Neurosci. 2024; 17:1386735.

PMID: 38883980 PMC: 11177777. DOI: 10.3389/fnmol.2024.1386735.


References
1.
Bertram L, Lill C, Tanzi R . The genetics of Alzheimer disease: back to the future. Neuron. 2010; 68(2):270-81. DOI: 10.1016/j.neuron.2010.10.013. View

2.
Gonzalez-Alegre P . Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacol Ther. 2007; 114(1):34-55. DOI: 10.1016/j.pharmthera.2007.01.003. View

3.
Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

4.
Patel N, Hoang D, Miller N, Ansaloni S, Huang Q, Rogers J . MicroRNAs can regulate human APP levels. Mol Neurodegener. 2008; 3:10. PMC: 2529281. DOI: 10.1186/1750-1326-3-10. View

5.
Heyer M, Pani A, Smeyne R, Kenny P, Feng G . Normal midbrain dopaminergic neuron development and function in miR-133b mutant mice. J Neurosci. 2012; 32(32):10887-94. PMC: 3752074. DOI: 10.1523/JNEUROSCI.1732-12.2012. View